A single-center cohort experience of raltegravir in salvage patients failing therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 5, 2010, Pages 666-667

  Teague, Alastair ^a   Scott, Chris ^a   Bower, Mark ^a   Gazzard, Brain ^a   Nelson, Mark ^a   Stebbing, Justin ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DARUNAVIR; ETRAVIRINE; RALTEGRAVIR;

CD4 LYMPHOCYTE COUNT; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETTER; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; PYRROLIDINONES; SALVAGE THERAPY;

EID: 77950282163     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ba4845     Document Type: Letter

References (11)

1. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-365.
2. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
3. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515.
4. Maiga AI, Malet I, Soulie C, et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02-AG subtypes. Antivir Ther. 2009;14:123-129.
5. Ceccherini-Silberstein F, Malet I, D'Arrigo R, et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009; 11:17-29.
6. Malet I, Delelis O, Soulie C, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother. 2009;63:795-804.
7. Delelis O, Malet I, Na L, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009;37:1193-1201.
8. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemo-ther. 2008;52:1351-1358.
9. De Castro I, Braun J, Charreau I, et al; and the ANRS 138 Study Group. Switch from enfuvirtide to raltegravir in highly treatment experienced HIV-1 infected patients: a ramdo-mised open-label non-inferiority trial. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada.
10. Goldwirt L, Braun J, de Castro N, et al. Tipranavir and darunavir pharmacokinetics in patients switching from enfuvirtide to ralte-gravir: a sub-study of the ANRS 138 EASIER trial [abstract 0-12]. Presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy; April 15-17, 2009; Amsterdam, The Netherlands.
11. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24 [abstract 70aLB, 2009]. Presented at: Sixteenth Conference on Retroviruses and Opportunistic Infections, February 5, 2009; Montreal, Canada